MDGL - シンタ・ファ―マシュ―ティカルズ (Madrigal Pharmaceuticals Inc.) シンタ・ファ―マシュ―ティカルズ

 MDGLのチャート


 MDGLの企業情報

symbol MDGL
会社名 Madrigal Pharmaceuticals Inc (シンタ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 マドリガル・ファーマシューティカルズ(Madrigal Pharmaceuticals Inc)(旧名:Synta Pharmaceuticals Corp.)は臨床病期のバイオ医薬品会社である。同社は心血管代謝疾患および非アルコール性脂肪性肝炎(NASH)の治療用の治療候補の開発・商業化に従事する。主力製品であるMGL-3196は、NASHの治療用第Ⅱ相準備の1日1回、経口、肝臓特異的選択甲状腺ホルモン受容体-b(THR-b)アゴニスト、および異型接合性および同型接合性家族性高コレステロール血症(FH)である。その製品パイプラインには、NASHとFHの治療に使用されるMGL-3745も含まれる。MGL-3196は、健康なボランティアで第I相単回投与および複数回投与試験を完了し、低密度リポタンパク質コレステロール、トリグリセリドレベルおよびリポタンパク質(a)を低下させるための異常脂質血症/高コレステロール血症のために開発されている。また、脂肪代謝を増加させることによって血漿・肝臓中のトリグリセリドを減少させ、抗糖尿病作用を示す。   シンタ・ファ―マシュ―ティカルズは米国のバイオ医薬品メ―カ―。主にがんや慢性炎症性疾患などの、重篤な病状や患者のための小分子薬の発見・開発・製品化に取り組む。臨床段階のがんの候補薬や、前臨床段階の炎症性疾患治療薬の開発プログラムを保有する。本社はマサチュ―セッツ州レキシントン。   Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
本社所在地 Four Tower Bridge 200 Barr Harbor Drive Suite 400 West Conshohocken PA 19428 USA
代表者氏名 Paul A. Friedman ポール・A・フリードマン
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 404-380-9263
設立年月日 36586
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 8人
url www.syntapharma.com
nasdaq_url https://www.nasdaq.com/symbol/mdgl
adr_tso
EBITDA EBITDA(百万ドル) -32.32700
終値(lastsale) 199.3138
時価総額(marketcap) 3062782215.7492
時価総額 時価総額(百万ドル) 2957.77
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 2467.465
当期純利益 当期純利益(百万ドル) -29.63200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Madrigal Pharmaceuticals Inc revenues was not reported. Net loss decreased 11% to $12.8M. Lower net loss reflects Interest income increase from $168K to $1.9M (income) Research and development decrease of 16% to $9.2M (expense) General and administrative decrease of 2% to $2.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.20 to -$0.90.

 MDGLのテクニカル分析


 MDGLのニュース

   Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Lowered by Zacks Investment Research  2020/10/24 06:12:41 Dispatch Tribunal
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday, Zacks.com reports. According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist […]
   The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout  2020/10/15 12:03:43 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X Genomics Inc (NASDAQ: TXG ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Denali Therapeutics Inc (NASDAQ: DNLI ) Immunomedics, Inc (NASDAQ: IMMU ) - The Hart-Scott-Rodino waiting period for its impending acquisition by Gilead Sciences, Inc. (NASDAQ: GILD ) expired, meeting one of the conditions necessary for the consummation of the transaction Insulet Corporation (NASDAQ: PODD ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mirati Therapeutics Inc (NASDAQ: MRTX ) NeoGenomics, Inc (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PRA Health Sciences Inc (NASDAQ: PRAH ) Replimune Group Inc (NASDAQ: REPL ) (abstract comprising data for its lead candidate RP1 in advanced solid tumors to be presented at the November Society for Immunotherapy of Cancer annual meeting made available online) Seres Therapeutics Inc (NASDAQ: MCRB ) SpringWorks Therapeutics Inc (NASDAQ: Full story available on Benzinga.
   The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street  2020/10/08 11:52:19 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cassava Sciences Inc (NASDAQ: SAVA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) InVitae Corp (NYSE: NVTA ) Insulet Corporation (NASDAQ: PODD ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Novocure Ltd (NASDAQ: NVCR ) Ocular Therapeutix Inc (NASDAQ: OCUL ) (preannounced positive Q3 revenues) Oncorus Inc (NASDAQ: ONCR ) (debuted on Friday) Prelude Therapeutics Inc (NASDAQ: PRLD ) Pulmonx Corp (NASDAQ: LUNG ) Qiagen NV (NYSE: QGEN ) Repligen Corporation (NASDAQ: RGEN ) Stoke Therapeutics Inc (NASDAQ: STOK ) (announced decision to dose STK-001 in children and adolescents in its Phase 1/2a study for Dravet syndrome) Surface Oncology Inc (NASDAQ: SURF ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx …
   Madrigal Pharmaceuticals : EASL 2020 | MarketScreener  2020/08/26 10:57:05 MarketScreener
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020 … | August 26, 2020
   Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals  2020/06/18 12:07:00 The Motley Fool
These two companies are going after the same target, but which one should you bet on today?
   Madrigal Pharmaceuticals : EASL 2020 | MarketScreener  2020/08/26 10:57:05 MarketScreener
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020 … | August 26, 2020
   Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals  2020/06/18 12:07:00 The Motley Fool
These two companies are going after the same target, but which one should you bet on today?
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO  2020/04/03 11:36:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precipio Inc (NASDAQ: PRPO ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Chanticleer Holdings Common Stock (NASDAQ: SONN ) Vaccinex Inc (NASDAQ: VCNX ) Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE ) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ )'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.
   Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals  2020/06/18 12:07:00 The Motley Fool
These two companies are going after the same target, but which one should you bet on today?
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO  2020/04/03 11:36:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precipio Inc (NASDAQ: PRPO ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Chanticleer Holdings Common Stock (NASDAQ: SONN ) Vaccinex Inc (NASDAQ: VCNX ) Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE ) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ )'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.
   10 US colleges and universities where female grads have gone on to secure more than $1 million in funding for their startups  2020/03/22 15:00:00 Business Insider
To date, there have been some 6,940 female company founders whose businesses have received more than $1 million in funding, according to research by UK business banking app Tide . A number of these successful female founders have graduated from a cluster of top schools in the US. Here are the top 10 US universities that have graduated the most female founders who've raised over $1 million, including MIT and Stanford University. Visit Business Insider's homepage for more stories . The state of women in the venture capital world is far from perfect. In 2019, female-founded companies only got 2.7% of VC funding, for a total of $3.54 billion, according to PitchBook . That's less than one company, WeWork, got during the same period, Fortune points out. WeWork received at least $5 billion. And yet, women are entering entrepreneurship at a high rate. From 2018 to 2019, women started an average of 1,817 new businesses per day in the US and now represent 42% of nearly 13 million businesses overall.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シンタ・ファ―マシュ―ティカルズ MDGL Madrigal Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)